Randomized, double blinded, crossover study to evaluate safety and pharmacokinetic/pharmacodynamic characteristics of PDA10 (recombinant human epoetin-alfa) compare to Eprex in healthy male volunteers

Trial Profile

Randomized, double blinded, crossover study to evaluate safety and pharmacokinetic/pharmacodynamic characteristics of PDA10 (recombinant human epoetin-alfa) compare to Eprex in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Erythropoietin (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Acronyms PG-EPO-Ph1
  • Most Recent Events

    • 14 Sep 2015 Results published in the Clinical Drug Investigation.
    • 08 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top